(VIANEWS) – TIETOEVRY (TIETO.OL), COLAS (RE.PA), UCB (UCB.BR) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio as yet. The payout ratio in itself isn’t a guarantee of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. TIETOEVRY (TIETO.OL)
81.43% Payout Ratio
TietoEVRY Oyj operates as a software and services company. It operates through six segments: Tietoevry Create, Tietoevry Banking, Tietoevry Care, Tietoevry Industry, Tietoevry Transform, and Tietoevry Connect. The Tietoevry Create segment provides digital agenda to create competitive products, as well as uses design, data, and cloud technologies for data-driven businesses. This segment also offers software and data engineering services. The Tietoevry Banking segment provides software products for digital transformation and financial institutions. The Tietoevry Care segment offers modular and interoperable software, reinventing Nordic health, and social care services. The Tietoevry Industry segment offers software and data solutions across various industries, such as public sector, pulp and paper, and utilities. The Tietoevry Transform segment provides enterprise-wide transformation across customers' business processes, applications and infrastructure. The Tietoevry Connect segment operates a cloud platform that provides a range of infrastructure choices ensuring security, resilience, and compliance for the customer's business. The company was formerly known as Tieto Oyj and changed its name to TietoEVRY Oyj in December 2019. TietoEVRY Oyj was founded in 1968 and is headquartered in Espoo, Finland.
Earnings Per Share
As for profitability, TIETOEVRY has a trailing twelve months EPS of kr20.1.
PE Ratio
TIETOEVRY has a trailing twelve months price to earnings ratio of 12.76. Meaning, the purchaser of the share is investing kr12.76 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.6%.
Moving Average
TIETOEVRY’s value is below its 50-day moving average of kr269.76 and way below its 200-day moving average of kr297.26.
Volume
Today’s last reported volume for TIETOEVRY is 158 which is 97.17% below its average volume of 5594.
Earnings Before Interest, Taxes, Depreciation, and Amortization
TIETOEVRY’s EBITDA is 13.37.
More news about TIETOEVRY.
2. COLAS (RE.PA)
80.86% Payout Ratio
Colas SA constructs and maintains transport infrastructure worldwide. It operates through three segments: Roads, Construction materials, and Railways. The company constructs and maintains roads and highways; and works on airfield runways and aprons, seaports, industrial sites, logistics and commercial premises, street construction and urban development, reserved-lane public transport, recreational amenities, environmental protection, etc. It also engages in the renovation, demolition, and deconstruction of buildings; and constructs small-scale civil engineering and drainage projects. In addition, the company produces and recycles construction materials, such as aggregates, emulsions and binders, asphalt mixes, ready-mix concrete, and bitumen. Further, it designs and engineers large projects; constructs, renews, and maintains rail networks, such as high-speed and conventional train lines, subways, and tramways; lays and maintains tracks, electrification, signaling/telecommunications, safety systems, ventilation, and fire detection/protection, as well as specific projects comprising bridge cranes, special branch lines, and repair of railway tunnels. Additionally, the company lays and maintains pipes and pipelines for the transport of water and energy, including the construction of turnkey gas compression stations, small-scale civil engineering works, and industrial services. It also engages in the manufacture, installation, and maintenance of road safety and signaling equipment; traffic management activities; and distribution of bitumen. The company was founded in 1929 and is headquartered in Paris, France. Colas SA is a subsidiary of Bouygues SA.
Earnings Per Share
As for profitability, COLAS has a trailing twelve months EPS of €9.09.
PE Ratio
COLAS has a trailing twelve months price to earnings ratio of 12.71. Meaning, the purchaser of the share is investing €12.71 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.65%.
Yearly Top and Bottom Value
COLAS’s stock is valued at €115.50 at 17:10 EST, under its 52-week high of €122.00 and above its 52-week low of €111.00.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.2%, now sitting on 15.8B for the twelve trailing months.
More news about COLAS.
3. UCB (UCB.BR)
78.24% Payout Ratio
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.7.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 48.6. Meaning, the purchaser of the share is investing €48.6 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.7%.
More news about UCB.
4. PUBLICIS GROUPE SA (PUB.PA)
56.31% Payout Ratio
Publicis Groupe S.A. provides marketing, communications, and digital business transformation services in North America, Europe, the Asia Pacific, Latin America, Africa, and the Middle East. The company offers advisory services for brand strategy, and repositioning and their identity under the Publicis Worldwide, Saatchi & Saatchi, Leo Burnett, Marcel, Fallon, and BBH brands; online advertising services under the Razorfish and Moxie brand names; crisis communications, press relations, public affairs, institutional relations, financial communications, and strategy management services; media consulting, planning, and buying services; performance marketing services; and e-commerce services. It also designs and delivers brand content for various channels, such as television, print, radio, cinema, and billboards, as well as digital, including display and social networks under the Prodigious, Harbor, and The Pub brand names. In addition, the company operates Epsilon PeopleCloud, a unified data and technology platform; and Publicis Sapient, a technological, digital, and consulting platform. Further, it provides healthcare communication services under the Digitas Health, Publicis Health Media, and Saatchi & Saatchi Wellness brands for the healthcare and well-being sectors. It serves clients in the automotive, retail, financial services, consumer products, and media sectors. Publicis Groupe S.A. was founded in 1926 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, PUBLICIS GROUPE SA has a trailing twelve months EPS of €5.15.
PE Ratio
PUBLICIS GROUPE SA has a trailing twelve months price to earnings ratio of 14.09. Meaning, the purchaser of the share is investing €14.09 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.3%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 14.75B for the twelve trailing months.
Yearly Top and Bottom Value
PUBLICIS GROUPE SA’s stock is valued at €72.56 at 17:10 EST, below its 52-week high of €77.94 and way higher than its 52-week low of €46.55.
More news about PUBLICIS GROUPE SA.
5. CTAC (CTAC.AS)
41.38% Payout Ratio
Ctac N.V. provides business and cloud integration services primarily in the Netherlands and Belgium. The company offers cloud, programme and change management, agile consultancy, application management, license management, service desk and coordination management, implementation, and consultancy and advice services. It also provides various solutions for cloud infrastructure, SAP S/4HANA, workplace, cyber security, unified commerce, integration, data management, data and analytics, customer experience, and innovation. In addition, the company offers SAP data warehouse, security assessment, fiori, s/4 move and hana, ECC, business warehouse, analytics, and EVM; data sync manager, ometa, binder dam, winshuttle, winshuttle evolve, inriver pim, ETIM extension for inriver pim, mendix, and XV Retail; Fit4 Real Estate, omni customer loyalty, private cloud, pricing and promotion engine, and floating basket; and Microsoft azure public cloud, teams, route365 cooker session, sharepoint, and 365. It primarily serves retail, wholesale, manufacturing, real estate, and cross industries. The company was founded in 1992 and is headquartered in ‘s-Hertogenbosch, the Netherlands.
Earnings Per Share
As for profitability, CTAC has a trailing twelve months EPS of €0.29.
PE Ratio
CTAC has a trailing twelve months price to earnings ratio of 12.34. Meaning, the purchaser of the share is investing €12.34 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.36%.
Moving Average
CTAC’s value is under its 50-day moving average of €3.76 and under its 200-day moving average of €3.66.
More news about CTAC.
6. ERAMET (ERA.PA)
39.46% Payout Ratio
ERAMET S.A. operates as a mining and metallurgical company in France, Asia, Europe, North America, and internationally. The company extracts and processes manganese ore and nickel ore; and extracts and develops mineral sands. It also produces ferronickel, nickel pig iron, briquettes, nickel salts, high purity nickel, nickel ferroalloys, and alloy steel and casting; manganese alloys, such as high-carbon ferromanganese, silicomanganese, low and medium-carbon ferromanganese, and low-carbon silicomanganese for use in batteries, pigments, construction, and automotive industries; and mineral sands, such as titanium dioxide, high-purity pig iron, zircon, and ilmenite used in ceramics and pigments. In addition, it operates Moanda mine in Gabon; nickel mines in New Caledonia and Indonesia; and mineral sand mine in Senegal and Argentina. ERAMET S.A. was incorporated in 1880 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ERAMET has a trailing twelve months EPS of €8.87.
PE Ratio
ERAMET has a trailing twelve months price to earnings ratio of 8.45. Meaning, the purchaser of the share is investing €8.45 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.28%.
Volume
Today’s last reported volume for ERAMET is 8496 which is 84.35% below its average volume of 54320.
More news about ERAMET.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, 1’s stock is considered to be overbought (>=80).
More news about 1.
